Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics

Diana D Kang; Haoyuan Li; Yizhou Dong

doi:10.1016/j.addr.2023.114961

Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics

Adv Drug Deliv Rev. 2023 Aug:199:114961. doi: 10.1016/j.addr.2023.114961. Epub 2023 Jun 14.

Authors

Diana D Kang¹, Haoyuan Li², Yizhou Dong³

Affiliations

¹ Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; Genomics Institute, Precision Immunology Institute, Department of Oncological Sciences, Tisch Cancer Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
² Genomics Institute, Precision Immunology Institute, Department of Oncological Sciences, Tisch Cancer Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
³ Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; Department of Biomedical Engineering, The Center for Clinical and Translational Science, The Comprehensive Cancer Center; Dorothy M. Davis Heart & Lung Research Institute, Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, United States; Genomics Institute, Precision Immunology Institute, Department of Oncological Sciences, Tisch Cancer Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States. Electronic address: yizhou.dong@mssm.edu.

Abstract

The accelerated progress and approval of two mRNA-based vaccines to address the SARS-CoV-2 virus were unprecedented. This record-setting feat was made possible through the solid foundation of research on in vitro transcribed mRNA (IVT mRNA) which could be utilized as a therapeutic modality. Through decades of thorough research to overcome barriers to implementation, mRNA-based vaccines or therapeutics offer many advantages to rapidly address a broad range of applications including infectious diseases, cancers, and gene editing. Here, we describe the advances that have supported the adoption of IVT mRNA in the clinics, including optimization of the IVT mRNA structural components, synthesis, and lastly concluding with different classes of IVT RNA. Continuing interest in driving IVT mRNA technology will enable a safer and more efficacious therapeutic modality to address emerging and existing diseases.

Keywords: IVT mRNA; In vitro transcribed mRNA; mRNA structure.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

COVID-19*
Humans
Neoplasms*
RNA, Messenger / genetics
SARS-CoV-2 / genetics
Vaccines*

Substances

RNA, Messenger
Vaccines

Grants and funding

R35 GM144117/GM/NIGMS NIH HHS/United States